| 13.94 -1.04 (-6.94%) | 07-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.54 | 1-year : | 21.65 |
| Resists | First : | 15.87 | Second : | 18.54 |
| Pivot price | 10.73  |
|||
| Supports | First : | 10.43 | Second : | 7.07 |
| MAs | MA(5) : | 14.47 |
MA(20) : | 9.98 |
| MA(100) : | 6.37 |
MA(250) : | 3.89 |
|
| MACD | MACD : | 1.8 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 79  |
D(3) : | 82.2 |
| RSI | RSI(14): 66.7 |
|||
| 52-week | High : | 15.87 | Low : | 1.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SLS ] has closed below upper band by 22.7%. Bollinger Bands are 366.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 15.54 - 15.62 | 15.62 - 15.69 |
| Low: | 13.54 - 13.62 | 13.62 - 13.71 |
| Close: | 13.78 - 13.92 | 13.92 - 14.05 |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Mon, 06 Jul 2026
This Little-Known Stock Has Surged 550% in the Past Year - Yahoo Finance
Mon, 06 Jul 2026
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
Mon, 06 Jul 2026
Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Can Afford To Invest In Growth - Moomoo
Sun, 05 Jul 2026
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
Wed, 01 Jul 2026
SELLAS Life Sciences Group (SLS) Stock Looks Above Fair Value Before Key Trial Data - Yahoo Finance
Wed, 01 Jul 2026
Why SELLAS Life Sciences Group (SLS) Is Up 62.7% After Phase 3 REGAL Trial Nears Final Data - And What's Next - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 197 (M) |
| Shares Float | 185 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 27.6 (%) |
| Shares Short | 63,360 (K) |
| Shares Short P.Month | 57,070 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.5 % |
| Return on Equity (ttm) | -43.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -60.61 |
| PEG Ratio | 0 |
| Price to Book value | 23.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -97.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|